Prediction of response of skeletal metastases from cancer of the prostate to high activity 186Re HEDP therapy.

被引：0
|
作者：
McCready, VR
O'Sullivan, J
Dearnaley, D
Cook, G
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
来源：
JOURNAL OF NUCLEAR MEDICINE | 2002年 / 43卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1272
引用
收藏
页码：316P / 316P
页数：1
相关论文
共 50 条
  • [1] Unexpected hematological tolerance to high activity 186Re HEDP therapy for skeletal metastases in prostate carcinoma.
    McCready, VR
    O'Sullivan, J
    Norman, A
    Dearnaley, DP
    Treleaven, JG
    Binnie, D
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 313P - 313P
  • [2] PBSC Transplantation in patients receiving ablative doses of 186Re HEDP for skeletal secondaries from prostate cancer
    McCready, R
    Treleaven, J
    Al Deen, A
    Dearnaley, D
    Powles, R
    BONE MARROW TRANSPLANTATION, 1998, 21 : S227 - S227
  • [3] [186Re]-HEDP in the palliation of painful bone metastases from cancers other than prostate and breast
    Minutoli, F.
    Herberg, A.
    Spadaro, P.
    Pecorella, G. Restifo
    Baldari, S.
    Arico, D.
    Altavilla, G.
    Baldari, S.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 50 (04): : 355 - 362
  • [4] The response of skeletal metastases to high activities of rhenium 186 HEDP
    McCready, VR
    Dearnaley, D
    Trelevan, J
    Aldeen, A
    RADIOLOGY, 1999, 213P : 251 - 251
  • [5] Response of skeletal metastases to high activities of Rhentum 186 HEDP
    McCready, R
    Al-Deen, A
    Treleaven, J
    Dearnaley, D
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1213 - 1213
  • [6] The optimum method to determine the maximum tolerated activity for high activity Re186HEDP therapy with peripheral blood stem cell support for skeletal metastases from prostate cancer
    McCready, VR
    O'Sullivan, J
    Norman, A
    Treleaven, J
    Dearnaley, D
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S480 - S481
  • [7] Effect of high dose Rhenium 186 HEDP with stem cell support on skeletal metastases in prostate cancer
    Al-Deen, A
    McCready, VR
    Dearnaley, DP
    Treleaven, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S344 - S344
  • [8] High activity therapy for bone metastases from CA prostate using Re-186 HEDP and peripheral blood stem cell support
    McCready, VR
    David, D
    Trelevan, J
    Al-Deen, A
    RADIOLOGY, 1998, 209P : 438 - 438
  • [9] Comparison of PSA measurements and scintigraphy in patients with skeletal metastases from carcinoma of the prostate treated with high activities of Re 186 HEDP.
    McCready, VR
    O'Sullivan, JM
    Dearnaley, DP
    Treleaven, J
    Cook, G
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 412P - 413P
  • [10] The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer
    Binnie, D
    Divoli, A
    McCready, VR
    Dearnaley, D
    Flux, G
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (02) : 189 - 194
12345